^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Multiple Myeloma
    Drug:Ninlaro (ixazomib) (Proteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    02/03/2021
    Excerpt:
    Recommendations: Maintenance with lenalidomide is considered the standard of care for all MM patients post-ASCT [I, A]; bortezomib may be considered for patients with high-risk disease [II, B]. Ixazomib maintenance offers PFS benefit over placebo [I, A]...
    DOI:
    10.1016/j.annonc.2020.11.014
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Multiple Myeloma: Other Recommended Regimens: Ixazomib (category 2B).
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Multiple Myeloma: Therapy for previously treated multiple myeloma…Other Recommended Regimens… Ixazomib/cyclophosphamide/dexamethasone
    Secondary therapy:
    cyclophosphamide + dexamethasone
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    …the NCCN Panel has included ixazomib/dexamethasone as a treatment option for patients with relapsed/refractory MM who have received at least one prior therapy.
    Secondary therapy:
    dexamethasone
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    J Clin Oncol
    Title:

    Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

    Published date:
    10/06/2020
    Excerpt:
    TOURMALINE-MM4 met its primary endpoint with a 34.1% reduction in risk of progression or death with ixazomib versus placebo (median PFS since randomization, 17.4 v 9.4 months; hazard ratio [HR], 0.659; 95% CI, 0.542 to 0.801; P < .001; median follow-up, 21.1 months)....Ixazomib significantly benefitted patients who achieved complete or very good partial response postinduction (median PFS, 25.6 v 12.9 months; HR, 0.586; P < .001).
    DOI:
    10.1200/JCO.20.02060
    Trial ID:
    TOURMALINE MM4
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Leukemia
    Title:

    Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

    Published date:
    04/23/2020
    Excerpt:
    In the TOURMALINE-MM3 study, post-autologous stem cell transplantation maintenance therapy with the oral proteasome inhibitor ixazomib versus placebo significantly improved progression-free survival (PFS), with a favorable safety profile. With ixazomib versus placebo maintenance, deepening responses occurred in 139/302 (46%) versus 60/187 (32%) patients with very good partial response or partial response (VGPR/PR) at study entry (relative risk 1.41, P = 0.004)...
    DOI:
    10.1038/s41375-020-0819-8
    Trial ID:
    TOURMALINE-MM3